The QUIDAM study: Hydroquinidine therapy for the management of Brugada syndrome patients at high arrhythmic risk.

MLA

Andorin, Antoine, et al. “The QUIDAM Study: Hydroquinidine Therapy for the Management of Brugada Syndrome Patients at High Arrhythmic Risk.” Heart Rhythm, vol. 14, no. 8, Aug. 2017, pp. 1147–54. EBSCOhost, https://doi.org/10.1016/j.hrthm.2017.04.019.

APA

Andorin, A., Gourraud, J.-B., Mansourati, J., Fouchard, S., le Marec, H., Maury, P., Mabo, P., Hermida, J.-S., Deharo, J.-C., Delasalle, B., Esnault, S., Sadoul, N., Davy, J.-M., Leenhardt, A., Klug, D., Defaye, P., Babuty, D., Sacher, F., Probst, V., & Delasalle, B. (2017). The QUIDAM study: Hydroquinidine therapy for the management of Brugada syndrome patients at high arrhythmic risk. Heart Rhythm, 14(8), 1147–1154. https://doi.org/10.1016/j.hrthm.2017.04.019

Chicago

Andorin, Antoine, Jean-Baptiste Gourraud, Jacques Mansourati, Swanny Fouchard, Hervé le Marec, Philippe Maury, Philippe Mabo, et al. 2017. “The QUIDAM Study: Hydroquinidine Therapy for the Management of Brugada Syndrome Patients at High Arrhythmic Risk.” Heart Rhythm 14 (8): 1147–54. doi:10.1016/j.hrthm.2017.04.019.